CorEvitas Inflammatory Bowel Disease (IBD) Registry

Enrolling by invitation

Conditions studied: Inflammatory Bowel Diseases

In brief

This prospective, non-interventional research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for IBD in a cohort of patients cared for by gastroenterologists across North America. Secondary objectives include analyzing the epidemiology and natural history of the disease, its comorbidities, and current treatment practices.

Key facts

Study ID

NCT03162549

Run by

CorEvitas

People needed

2287

Starts

2017-03-27

Expected to finish

2100-12-01

Last updated by the study team

2025-10-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least 18 years of age or older.
• Willing and able to provide written consent for participation in the IBD Registry.
• Willing and able to provide Personally Identifiable Information (PII) which includes the following types of personal information at a minimum: full name, date of birth, sex, and home address zip code.
• Diagnosis of one of the following by a gastroenterologist:
• Crohn's disease
• Ulcerative colitis
• Prevalent users or new /incident users of an approved biologic drug or JAK inhibitor (Tofacitinib) for the treatment of UC or Crohn's disease.

You may not qualify if…

• Participating in or planning to participate in a clinical trial (Phase I - III) or a post-marketing study or registry (i.e. phase IV).∆

Where it is running

• CorEvitas, LLC — Waltham, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.